What does SOGIPHARMA do?

SOGIPHARMA is a pharmacy in Wavre. Public Limited, started on 6 March 1990, 2 establishments.

What is the address of SOGIPHARMA?

The registered office of SOGIPHARMA is located at Chaussée de Namur 5, 1300 Wavre.

Is SOGIPHARMA still active?

Yes. According to the CBE (29 October 2026) SOGIPHARMA is active, legal situation “Normale toestand”, started on 6 March 1990.

Is SOGIPHARMA registered on Peppol?

Yes, SOGIPHARMA is registered on the Peppol network with ID 0208:0440387324.

What is the enterprise number of SOGIPHARMA?

The enterprise number of SOGIPHARMA is BE0440387324.

When was SOGIPHARMA founded?

SOGIPHARMA was founded on 6 March 1990.

Who are the directors of SOGIPHARMA?

According to the 2025 annual accounts, the directors of SOGIPHARMA are: Pharmacies Servais SRL.

Is SOGIPHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 6 March 1990; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account; 2 establishments in the CBE.

How much profit did SOGIPHARMA make in 2025?

SOGIPHARMA posted a profit after taxes of € 16,514 in financial year 2025.

What is the revenue of SOGIPHARMA?

As a small company, SOGIPHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 114,207.

How many employees does SOGIPHARMA have?

According to the 2025 annual accounts, SOGIPHARMA has 0 full-time equivalents (FTE).

SOGIPHARMA (Public Limited) - Wavre - BE0440387324

Dossier SOGIPHARMA, printed on 29 October 2026 from databakkes.be/en/0440387324/sogipharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

SOGIPHARMA from Wavre, company number BE0440387324, closed financial year 2025 with a result of € 16,514 after tax. For that financial year SOGIPHARMA recorded a gross margin of € 114,207 and equity of € 484,629. Compared with financial year 2024, the result moved from € 25,755 to € 16,514. The company is profitable. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on June 11, 2026.

What it is worth Growing

€ 484,629

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 16,514

▼ 36% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 28,227

▲ 1% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 15,000 paid out

91 % of the profit went to the shareholders, mostly to Pharmacies Servais (100 % of the shares). That is where the money ends up.

People and assets in 2025

Full-time equivalents

Average over the fiscal year, from the social balance sheet.

Vehicles and equipment

€ 12,489

▼ 44% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 9 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 913,016

▲ 68% vs 2024

€ 98,092 is repaid this year. At this pace the long-term loan is gone in ≈ 9 years.

Owed to suppliers

€ 895

▼ 69% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 8,895

▼ 17% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 81,700 Gross margin 2022: € 81,700 First fiscal year in the series	€ 119,695 Gross margin 2023: € 119,695 ▲ 47% vs 2022 (€ 81,700) Favourable step	€ 121,221 Gross margin 2024: € 121,221 ▲ 1% vs 2023 (€ 119,695) Favourable step	€ 114,207 Gross margin 2025: € 114,207 ▼ 6% vs 2024 (€ 121,221) Unfavourable step	▼ 6%
Profit after taxes	€ -18,589 Profit after taxes 2022: € -18,589 First fiscal year in the series	€ 19,563 Profit after taxes 2023: € 19,563 ▲ € 38,152 vs 2022 (€ -18,589) Favourable step	€ 25,755 Profit after taxes 2024: € 25,755 ▲ 32% vs 2023 (€ 19,563) Favourable step	€ 16,514 Profit after taxes 2025: € 16,514 ▼ 36% vs 2024 (€ 25,755) Unfavourable step	▼ 36%
Equity	€ 472,797 Equity 2022: € 472,797 First fiscal year in the series	€ 482,360 Equity 2023: € 482,360 ▲ 2% vs 2022 (€ 472,797) Favourable step	€ 483,115 Equity 2024: € 483,115 Unchanged (€ 482,360) Favourable step	€ 484,629 Equity 2025: € 484,629 Unchanged (€ 483,115) Favourable step
Total debts	€ 803,817 Total debts 2022: € 803,817 First fiscal year in the series	€ 664,608 Total debts 2023: € 664,608 ▼ 17% vs 2022 (€ 803,817) Favourable step	€ 581,716 Total debts 2024: € 581,716 ▼ 12% vs 2023 (€ 664,608) Favourable step	€ 940,386 Total debts 2025: € 940,386 ▲ 62% vs 2024 (€ 581,716) Unfavourable step	▲ 62%
Cash	€ 86,631 Cash 2022: € 86,631 First fiscal year in the series	€ 35,498 Cash 2023: € 35,498 ▼ 59% vs 2022 (€ 86,631) Unfavourable step	€ 28,025 Cash 2024: € 28,025 ▼ 21% vs 2023 (€ 35,498) Unfavourable step	€ 28,227 Cash 2025: € 28,227 ▲ 1% vs 2024 (€ 28,025) Favourable step	▲ 1%
Land & buildings	€ 409,117 Land & buildings 2022: € 409,117 First fiscal year in the series	€ 389,901 Land & buildings 2023: € 389,901 ▼ 5% vs 2022 (€ 409,117) Unchanged	€ 386,356 Land & buildings 2024: € 386,356 ▼ 1% vs 2023 (€ 389,901) Unchanged	€ 929,416 Land & buildings 2025: € 929,416 ▲ 141% vs 2024 (€ 386,356) Unchanged	▲ 141%
Retained profit	€ 4,341 Retained profit 2022: € 4,341 First fiscal year in the series	€ 13,904 Retained profit 2023: € 13,904 ▲ 220% vs 2022 (€ 4,341) Favourable step	€ 14,659 Retained profit 2024: € 14,659 ▲ 5% vs 2023 (€ 13,904) Favourable step	€ 16,173 Retained profit 2025: € 16,173 ▲ 10% vs 2024 (€ 14,659) Favourable step	▲ 10%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 10,000 Dividend 2023: € 10,000 Unchanged (€ 0) Unchanged	€ 25,000 Dividend 2024: € 25,000 ▲ 150% vs 2023 (€ 10,000) Unchanged	€ 15,000 Dividend 2025: € 15,000 ▼ 40% vs 2024 (€ 25,000) Unchanged	▼ 40%
Bank debt	€ 744,747 Bank debt 2022: € 744,747 First fiscal year in the series	€ 649,480 Bank debt 2023: € 649,480 ▼ 13% vs 2022 (€ 744,747) Favourable step	€ 541,956 Bank debt 2024: € 541,956 ▼ 17% vs 2023 (€ 649,480) Favourable step	€ 913,016 Bank debt 2025: € 913,016 ▲ 68% vs 2024 (€ 541,956) Unfavourable step	▲ 68%
Balance sheet total	€ 1,276,614 Balance sheet total 2022: € 1,276,614 First fiscal year in the series	€ 1,146,969 Balance sheet total 2023: € 1,146,969 ▼ 10% vs 2022 (€ 1,276,614) Unchanged	€ 1,064,832 Balance sheet total 2024: € 1,064,832 ▼ 7% vs 2023 (€ 1,146,969) Unchanged	€ 1,425,015 Balance sheet total 2025: € 1,425,015 ▲ 34% vs 2024 (€ 1,064,832) Unchanged	▲ 34%

Key figures of SOGIPHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to SOGIPHARMA?

What happened at SOGIPHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 11, 2026 New annual accounts for financial year 2025: profit of € 16,514 (▼ 36% vs 2024). Source: NBB ↗
Dec 14, 2010 New establishment in Lasne. KBO
Feb 10, 1994 New establishment in Lasne. KBO
Mar 6, 1990 Start of the company according to the CBE. KBO

In short

From € 18,589 loss in 2022 to € 16,514 profit in 2025.

Paid € 16,967 in corporate taxes since 2022.

Best year ever: 2024, with € 25,755 profit.

Paid out € 50,000 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Pharmacies Servais 100%

SOGIPHARMA

Behind SOGIPHARMA is Pharmacies Servais SRL. The shares are held by Pharmacies Servais (100%).

Directors

According to the 2025 annual accounts

Pharmacies Servais SRL

Director · represented by Servais Emmanuelle

Also active at: LA PHARMACIE DU PARC, APOTHEEK DE LINDE, PHARMACENTRE, GROUPEMENT DES PHARMACIES COOPERATIVES DES PROVINCES FRANCOPHONES, Pharmacie d’Ohain, PHARMACIE DU PRINCE D'ORANGE

Shareholders

Pharmacies Servais

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Chaussée de Namur 5

1300 Wavre

2.065.658.748

Chaussée de Louvain 420

1380 Lasne

Active since 10 February 1994

2.205.974.493

Rue des Saules 25

1380 Lasne

Active since 14 December 2010

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 4 companies are registered at this address.

All companies at this address →

PHARMACENTRE same network

€ 75,069 gross margin · 2025

PHARMACIES SERVAIS same network

€ 52.2 million revenue · 2025

Pharmacie d’Ohain same network

€ 50,690 gross margin · 2025

PHARMATEAM INVEST

€ 630,000 revenue · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0440.387.324

VAT number

BE 0440.387.324

Registered office

Chaussée de Namur 5, 1300 Wavre

Names & denominations

SOGIPHARMA

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

6 March 1990

Peppol

Active · Active since 21 Oct 2026

Contact

[email protected]

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

View on CBE Public ↗ Annual accounts (NBB) ↗

SOGIPHARMA

Financials

What happened to SOGIPHARMA?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions